NY-ESTÉE-LAUDER
30.9.2022 12:46:43 CEST | Business Wire | Press release
In the 30 years since Evelyn H. Lauder launched The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) and co-created the Pink Ribbon in 1992, The Campaign’s mission to help create a breast cancer-free world for all has remained steadfast. The Estée Lauder Companies (ELC) has a long-standing commitment to helping women and girls achieve their highest potential. As ELC’s largest corporate social impact program, The Campaign is a cornerstone of ELC’s social investments in women’s advancement and health, uniting people everywhere to positively impact the global breast cancer community. As breast cancer is the most commonly diagnosed cancer in the world,1 ELC's continued commitment to improving the lives of all those touched by the disease remains unwavering.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005040/en/
The Estée Lauder Companies Launches 2022 Breast Cancer Campaign (Graphic: Business Wire)
Together, The Estée Lauder Companies’ Breast Cancer Campaign and The Estée Lauder Companies Charitable Foundation (ELCCF) have funded more than $108 million globally for lifesaving research, education and medical services, with more than $86 million funding medical research grants through the Breast Cancer Research Foundation (BCRF). Founded in 1993 by Evelyn H. Lauder, BCRF is dedicated to advancing the world’s most promising research. ELC’s commitment to breast cancer research, spanning three decades, has been transformative. In partnership with BCRF, The Campaign has helped fuel research across the entire spectrum of the disease—from tumor biology, lifestyle and genetics, survivorship, treatment, and metastasis—making an indelible mark in the diagnosis, care, and prevention of breast cancer. In addition, The Campaign supports more than 60 organizations worldwide, facilitating real change aligned to the diverse needs of local communities.
Deaths from breast cancer have declined 42% in the U.S. since the late 1980s.2 However, that progress has not been experienced equally and certain populations are at higher risk for adverse breast cancer outcomes. At every age, Black women in the U.S. are more likely to die from breast cancer than any other race or ethnic group, and mortality rates remain 41% higher than in white women, despite lower incidence.3 The Campaign has and continues to support BCRF-funded research that identifies and addresses disparities that exist across the entire breast cancer landscape. ELCCF’s $15 million donation over five years will fund a new BCRF research initiative to accelerate The Campaign’s goal of reducing breast cancer disparities and improving outcomes. This comprehensive study of the intersection of social determinants of health, comorbidities, and the biology of breast cancer in Black women has the potential to significantly impact breast cancer disparities globally. It will help advance personalized breast cancer health care across prevention, diagnosis, and treatment for those at most risk of dying from the disease, and has the potential to be groundbreaking for the global breast cancer community.
William P. Lauder, Executive Chairman of The Estée Lauder Companies Inc. shared, “The potential impact that this BCRF initiative will have in accelerating a crucial area of research cannot be overstated, as we collectively work towards a more equitable future for all. I know my mother, Evelyn Lauder, would be so proud of the advancements we have made through research, education, access to care and our commitment to help end breast cancer.”
In the past 30 years globally, The Campaign has:
- Funded medical research and fellowships, as well as medical resources, services and centers, including access to mammograms and screenings for vulnerable groups with limited access to healthcare.
- Advanced conversations on the importance of breast health education and early detection by facilitating discussions between the breast cancer community, medical experts and key opinion leaders.
- Supported therapy and counseling programs to help improve the lives of people with breast cancer and their families.
- Distributed educational materials and more than 180 million Pink Ribbons to spread awareness.
“The Estée Lauder Companies’ success is deeply rooted in living our shared values. Reflecting on the last 30 years, the incredible progress made by The Breast Cancer Campaign has had a lasting impact on our global community. As an authentic cornerstone of our commitments, The Campaign has been supported by our employees, consumers and partners worldwide. Today, it continues to inspire action in people everywhere. As a Beauty Inspired, Values Driven company, we look forward to the future and are committed to advancing positive change for all of those touched by this disease,” said Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies Inc.
The Campaign will take the following actions aligned to its mission for its 30th Anniversary:
- Double-down on The Campaign’s efforts to reduce breast cancer disparities and improve health outcomes.
- Mobilize ELC’s passionate employees to unite in action and support more than 60 organizations worldwide.
- Show support through 18 of ELC’s brands: Estée Lauder, Clinique, Lab Series, Origins, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, and Dr.Jart+. Each will donate to BCRF and/or local cancer-focused organizations around the world, with brand participation varying by market.
- Convene breast cancer thought leaders and advocates to advance education and share important messages about the disease.
- Drive additional donations to BCRF through ELCompanies.com/BreastCancerCampaign and various points of engagement.
- Accelerate communications on social media including TikTok and various Meta platforms to foster awareness, fundraising and engagement, including new calls-to-action.
- Unveil a new series of global stories demonstrating the diversity of the disease.
- Continue The Campaign’s tradition of illuminating buildings, monuments and landmarks around the world in glowing pink lights to raise awareness of breast health, including the Empire State Building, New York City; the Eiffel Tower, Paris; LOTTE WORLD TOWER, Seoul.
- Continue producing and distributing informative materials and Pink Ribbons worldwide.
As long as breast cancer remains a life-threatening disease, The Estée Lauder Companies’ commitment to the meaningful work that must continue will not waiver. It’s #TimeToEndBreastCancer.
ABOUT THE ESTÉE LAUDER COMPANIES INC.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-I
_____________________________
1 World Health Organization
2 American Cancer Society® Facts and Figures 2021-2022
3 American Cancer Society® Key Statistics for Breast Cancer
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220930005040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 07:00:00 CEST | Press release
Hyaluronic acid product for knee osteoarthritis available in the EU and Switzerland from May 2026 Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of
Murata Begins Mass Production of Seven Automotive MLCCs with World-leading Capacitance for Their Rated Voltage and Size, Supporting Stable Operation of In-vehicle Systems and Greater Design Flexibility8.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of seven AEC-Q200-qualified multilayer ceramic capacitors (MLCCs) that achieve the world’s largest capacitance for a given rated voltage and size*, supporting stable operation of in-vehicle systems and greater design flexibility. Five parts in the GCM series are rated at 2.5-4 Vdc, targeting IC peripheral circuits in advanced driver assistance systems (ADAS) and autonomous driving (AD) applications. The remaining two MLCCs are rated at 25 Vdc for in-vehicle power line applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407486750/en/ [Murata Manufacturing Co., Ltd.] Seven automotive MLCCs In recent years, as ADAS and AD technologies advance, the number and performance level of systems installed in vehicles have continued to increase. As a result, demand for higher capacitance low-voltage MLCCs used around ICs has grown to e
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)7.4.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees. The equity awards were granted on April 1, 2026 and consisted of options to purchase an aggregate of 117,445 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 55,875 shares. The options have an exercise price per share equal to $5.62, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted s
SLB OneSubsea and Subsea7 Sign Collaboration Agreement with PETRONAS Suriname7.4.2026 22:05:00 CEST | Press release
Partnership enables early engagement to co-develop cost-effective solutions and accelerate subsea development in Suriname Global energy technology company SLB (NYSE: SLB) today announced the signing of a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331210557/en/ SLB OneSubsea has signed a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea soluti
Nadia Karkar Joins 500 Global as Managing Partner7.4.2026 19:43:00 CEST | Press release
Former TPG Rise executive joins as Managing Partner as the firm expands its global investment platform. 500 Global today announced the appointment of Nadia Karkar as Managing Partner as the firm expands its global investment platform. Nadia’s appointment follows the recent announcement of the appointment of Atul Mehta — former Chief Investment Officer of the International Finance Corporation — to 500 Global's Board of Directors, and reflects the firm's continued build-out of the leadership and capabilities required to deliver on its next stage of global growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407719214/en/ Nadia Karkar Joins 500 Global as Managing Partner Nadia joins from TPG Rise, the $31 billion impact investing platform of TPG Inc., where she most recently served as Head of Business Development, responsible for product innovation, strategic partnerships and corporate development. She played a central rol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
